Viking Therapeutics Declined in July, and why its Long-Term Prospects are UndiminishedThe Motley Fool • 08/06/26
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover TargetThe Motley Fool • 07/30/26
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire • 07/29/26
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?Zacks Investment Research • 07/28/26
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026PRNewsWire • 07/22/26
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1The Motley Fool • 07/18/26
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes.The Motley Fool • 07/18/26
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteZacks Investment Research • 07/17/26
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?Zacks Investment Research • 07/17/26
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 07/10/26
Viking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing StrengthFXEmpire • 07/09/26
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market TodayZacks Investment Research • 07/08/26